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Abstract
Background: The accumulation of advanced glycation endproducts in articular cartilage has been suggested as an
etiologic factor in the development and progression of knee osteoarthritis (KOA).
Methods: We conducted a prospective cohort study of skin advanced glycation endproducts (sAGEs) measured
non-invasively by skin intrinsic fluorescence and the relationship between sAGE KOA progression in 160 men and
287 women in a sub-cohort of the Osteoarthritis Initiative at a single site. KOA progression was measured by yearly
changes in Osteoarthritis Research Society International (OARSI)-defined joint space narrowing (JSN) and by yearly
changes in joint space width (JSW) from baseline to 48 months. Sex-stratified repeated measures, mixed models to
account for correlation between the knees within persons and adjusted for age, body mass index (BMI), Kellgren-
Lawrence (KL) grade, beam angle and rim-to-rim distance were utilized.
Results: Increasing tertiles of sAGE measured at 36 months were associated with greater JSN over 4 years in men
but not in women. The percentage of knees with JSN at 48 months, by tertiles of sAGE, were 7.0%, 16.0% and 17.
7% in men (p for linear trend = 0.03) and 11.4%, 14.4% and 8.4% in women (p for linear trend = 0.33). Using change
in JSW as the outcome, a similar trend was found in men but it was not statistically significant in fully adjusted
models and no association was found in women.
Conclusion: This study provides preliminary evidence that sAGEs independent of age and BMI, are associated with
knee JSN in men but not in women.
Keywords: Advanced glycation endproducts, Knee osteoarthritis, Progression, Sex differences
Background
Osteoarthritis (OA) is characterized by the progressive
destruction of articular cartilage and is strongly and
positively associated with chronological age, but the
mechanism by which aging contributes to this increased
susceptibility is largely unknown. Recently the hypothesis
has been promulgated that accumulation of advanced
glycation endproducts (AGEs) that are associated with
cumulative glycemic exposure, oxidative stress and aging
might explain some or most of this association [1].
Alterations in the extracellular matrix and loss of resident
cells to repair this matrix damage induced by oxidative
stress and AGEs have been suggested as explanations for
the progressive articular damage associated with aging.
AGEs are the endproducts of spontaneous reactions of re-
ducing sugars with proteins, or non-enzymatic glycation
found in tissues throughout the human body. These
sugar-protein products are stabilized in humans through a
group of complicated biochemical reactions (Maillard re-
actions) that produce a range of pigmented, fluorescent
and glucose-derived protein cross-links that are collect-
ively known as AGEs. Most AGEs have not been charac-
terized in human systems; therefore a few markers of the
non-enzymatic glycation process have been used to study
their effects on human biology. AGEs form at accelerated
rates in many tissues in patients with diabetes mellitus
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and therefore have been largely studied to better under-
stand this disease and its complications [2–4]. AGEs have
been associated with the several other age-related chronic
diseases including Alzheimer’s dementia, and cardiovascu-
lar disease [5–8]. Pentosidine, a fluorescent AGE formed
by lysine and arginine residues, is a highly sensitive
marker of AGE and is often used to characterize the whole
family of AGEs in human tissues. Pentosidine has been
shown to accumulate in the collagen matrix of skin, lens,
and articular cartilage [1].
Of particular importance in OA, low turnover tissues
such as articular cartilage appear to be particularly sensi-
tive to the accumulation of AGEs regardless of glucose
metabolic status [1, 7]. Several lines of evidence have
been reported that suggest that the accumulation of
AGEs in articular cartilage might be an important mech-
anism in the association between aging and OA. First,
articular chondrocytes express the receptors of advanced
glycation endproducts in humans [9]. Second, in dog
models of experimentally induced OA, elevated levels of
AGEs lead to more severe OA based upon histologic
grading, increased collagen damage and enhanced
release of proteoglycans [10]. Third, human articular
cartilage incubated in AGEs demonstrates a dose-
dependent increase in AGEs that is associated with in-
creased stiffness of the collagen network and decreases
in the tensile strength of the collagen network suggesting
that accumulation of AGE crosslinks might be an impor-
tant putative mechanism in the development or progres-
sion of OA [11]. Senoult et al. [12] found increased levels
of pentosidine, an advanced glycation endproduct in the
serum and synovial fluid of patients with knee OA com-
pared to controls. Both the serum and synovial fluid
pentosidine levels correlated with synovial fluid cartilage
oligomeric matrix protein (COMP) but not with radio-
graphic staging of the knee OA. Vos et al. found in cross-
sectional analysis that skin pentosidine was associated
with increased severity and progression of knee and hip
OA [13, 14].
This evidence adds additional support to the concept
that AGEs may act as novel biomarkers of the incidence
and progression of knee OA. However, not all studies
are supportive of this hypothesis. Hunter et al. did not
find correlation between urinary pentosidine and cartil-
age loss in the Boston Osteoarthritis of the Knee Study
[15]. In addition, Vos et al. identified an inverse relation-
ship of cartilage pentosidine levels and microscopic,
histological and biochemical cartilage damage in samples
obtained in total knee replacement [16].
Advanced glycation endproduct serum assays are not
widely available due to a complex mixture of trace
compounds in tissue proteins and the sophisticated and
expensive techniques, such as gas chromatography and
mass spectrometry, which are needed to reliably and
precisely measure these products. However, when pento-
sidine is exposed to light in the near-UV and blue
spectrum, it emits characteristic wavelengths of light
called autofluorescence. Levels of the pentosidine found
in skin biopsy specimens are highly correlated with
collagen-linked fluorescence of the skin. Recently several
groups have developed non-invasive means to measure
skin fluorescence and thus indirectly measure skin AGE
levels [17–19]. These skin fluorescence levels have been
shown to be correlated with collagen-linked fluorescence
of the skin and AGE levels in skin biopsy specimens in
both human and animal models [20, 21].
We were therefore interested in exploring the associ-
ation of skin fluorescence with the progression of knee
OA by measuring changes in joint space narrowing




This is an approved ancillary study to the Osteoarthritis
Initiative (OAI) performed at a single clinical center, the
Brown University, Pawtucket, Rhode Island site (n = 1000
participants, 2000 knees). Detailed information about the
OAI protocol is available (http://oai.epi-ucsf.org) [22].
Briefly, the OAI is a multi-center, longitudinal, prospective
observational study of knee OA. The overall aim of the
OAI is to develop a public domain research resource to
facilitate the scientific evaluation of biomarkers for osteo-
arthritis as potential surrogate endpoints for disease onset
and progression. In 2004–2006, the OAI collected baseline
data from four study sites (i.e. Baltimore MD, Columbus
OH, Pittsburgh PA and Pawtucket RI, USA) totaling
4796 patients with established OA or at risk of devel-
oping knee OA.
Skin intrinsic fluorescent measurements were performed
at 36 months at a single clinical center in Pawtucket RI in
728 of the 1000 participants. Knees were excluded from
this analysis if they had (1) severe radiographic OA, as
evidenced by a baseline Kellgren/Lawrence (K/L) grade of
4 (n = 38) or (2) primarily lateral JSN at any point from
baseline to 48 months (n = 94). Additionally, specific
follow-up knee data were excluded if there was missing or
unsatisfactory knee positioning on the follow-up radio-
graph (n = 250). Unsatisfactory knee positioning was
indicated if the difference in rim distance (from the tibial
plateau to the tibial rim closest to the femoral con-
dyle) between that follow-up visit and the baseline
visit was >2 mm. This is done to minimize possible
effects of knee position on measurement error in the
measurement of joint space width (JSW). The analytic
cohort comprised 447 participants (733 knees) with a
K/L grade of 0–3, and who had skin AGE (sAGE)
data available at 36 months (see flow diagram, Fig. 1).
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Repeated radiographic measurements at 12, 24, 36
and 48 months were included in this analysis. Due to
potential alterations in sAGEs, 43 patients with
diabetes mellitus were removed from the analytic
dataset.
Radiographic assessment of knees
In the OAI, current assessment of radiographs involved
both semi-quantitative assessment of JSN and quantita-
tive assessment of JSW. Using the semi-quantitative
approach, JSN was scaled at grade intervals of 0.2 (i.e.
1.2, 1.4, etc.) and any change by grade 0.2 in the medial
compartment was considered progression [23].
A quantitative approach was used to provide a precise
measure of JSW in millimeters between the adjacent
bones of the knee [24, 25]. Multiple JSWs were mea-
sured at fixed locations along the joint in the medial
compartment, denoted as JSW(x), at intervals of 0.025
for x = 0.15–0.30. The reproducibility of this technique
and the responsiveness to change have been documented
elsewhere [26–28] including one study using OAI data,
which demonstrated responsiveness that compared
favorably to magnetic resonance imaging (MRI) [26].
We used medial JSW at x = 0.25 with the best respon-
siveness of change to quantify the progression of OA
[28]. We defined the repeated measures of the changes
in JSW from baseline to 12, 24, 36 and 48 months as
one of the outcome variables. To account for changes in
beam angle and alignment at each visit, which intro-
duces measurement error in serial JSW measurement
and JSN assessments, we also adjusted for changes of
the beam angles and rim distances (from the tibial
plateau to the tibial rim closest to the femoral condyle
between follow-up visits and baseline). For these
analyses, we used the publically available quantitative
JSW measurements (version 06/17/2013, online at
http://oai.epi-ucsf.org) and the semi-quantitative JSN
readings (kXR_SQ_BU, version 06/17/2013, online at
http://oai.epi-ucsf.org.
Skin intrinsic fluorescence measurement
Levels of AGEs were determined using spectroscopic
measurement of sAGEs at the 36-month visit [19, 21].
We measured sAGE using the SCOUT DS (VeraLight
Inc., Albuquerque, NM). sAGE measures skin intrinsic
fluorescence using a specifically designed fiber-optic
probe that sends near-UV and blue excitation light to
the forearm skin of the subject and the resulting skin
fluorescence and diffuse reflectance is detected by a
charge-coupled device array. In addition, a white-light-
emitting diode (LED) illuminated the skin to measure
the subject’s skin tone and correct the measured fluores-
cence for skin tone to yield skin intrinsic fluorescence.
The sequentially illuminated, excitation LEDs in the
instrument have peak wavelengths of 375, 405, 420, 435,
and 460 nm. The optical radiation emitted from the skin
is dispersed in a modified research-grade spectrometer.
A mathematical algorithm is applied to spectrum results
to adjust for hemoglobin, skin pigmentation and light
scattering. Thus, the subject-specific distortion of the
emitted fluorescence is normalized by the measured skin
tone to yield the intrinsic fluorescence. For our analysis,
we used the excitation wavelength of 375 nm and emis-
sion wavelengths of 435–660 nm, which are correlated
with crosslinks of collagen, flavin adenine dinucleotide
(FAD) and nicotinamide adenine dinucleotide hydride
(NADH) and thus, represent sAGEs and oxidative stress
most likely associated with accumulation in articular
cartilage. The output is scaled 0–100, with higher levels
associated with higher levels of AGEs.
Covariates
Sociodemographic factors measured at baseline included
race/ethnicity, age, sex, smoking status, education years,
and income. Race/ethnicity (African American, white or
other race) was self-reported. Age, sex and smoking
status (never, past or current) were self-reported. Body
mass index (BMI) was measured by physical exam and
was calculated from measured height and weight (weight
(kg)/height (m)2) was classified into normal weight (BMI
18.5–24.9), overweight (BMI 25.0–29.9), or obese (BMI
≥30). Waist circumference was measured at the umbil-
icus twice and the average taken. sAGE levels were
examined by smoking status and found to be equivalent
Fig. 1 Flow diagram for determination of Ostearthritis Initiative (OAI)
participants used in analysis. sAGE skin advanced glycation endproduct,
KL Kellgren/Lawrence grade
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in current and past smokers. The smoking status
variable was restructured for further analysis into never
smoked versus current and past smoking.
Statistical analysis
The focus of the analysis was to assess the association
between sAGEs and change in JSN and JSW over the
study period. As sAGEs were not normally distributed
we rank-ordered the data and categorized sAGEs into
sex-specific tertiles. The outcomes were repeated mea-
sures of the change in JSN and JSW from baseline to 12,
24, 36 and 48 months. We tested for interaction by sex
using the F test and found it was significant (p = 0.007
for JSN and p = 0.008 for JSW). Therefore, separate
models of repeated measures for men and women were
used to test the independent association between sAGEs
and the change in JSN and JSW over time. Because of
the hierarchical structure of the data (participant, knee,
measures over time), linear mixed models were used to
account for within-subject correlation and for the correl-
ation of repeated measures at the knee for JSW and lo-
gistic mixed models for JSN. We additionally adjusted
for beam angle and rim-to-rim distance to account for
changes in JSW and JSN due to changes in position.
We evaluated crude models and models adjusted for
age, BMI, and baseline K/L grade to evaluate the effect
of increasing tertiles of sAGEs on JSN and JSW over the
4-year period from baseline to year 4. While smoking
status and hypertension were associated with sAGE
levels, they were not associated with progression of knee
OA in men, and when added to our models in women
they did not change the results of the analysis, and
therefore these variables were not incorporated into our
multiple variable models. All data analyses were con-
ducted using SAS, version 9.2 (Cary, NC, USA).
Results
sAGE scores ranged from 18.7 to 69.5 in men and 17.8
to 59.7 in women. We evaluated 160 men (255 knees)
and 287 women (478 knees). Sex-specific ranges for each
tertile of sAGEs and the cross-sectional associations
between sAGEs and baseline characteristics are given in
Table 1. Only older age and hypertension were associ-
ated with increasing levels of sAGEs in both sexes. Past
and current smoking was associated with increasing
levels of sAGEs in men only. Of note in women, the
lowest tertile of sAGEs was associated with the greatest
abdominal circumference and the percentage of women
with obesity, contrary to the direction that was expected.
Due to multiple exclusions and measurement of
sAGEs at a single site, we were concerned about poten-
tial selection bias and issues of generalizability. We
therefore compared our sample to those excluded and to
the overall OAI sample (Additional file 1: Table S1). The
analytic sample differed from those excluded at the site
where sAGEs were measured in terms being a slightly
younger age compared to the excluded sample, and we
noted fewer changes in JSW over the 4 years of meas-
urement in the analytic sample when compared to the
excluded sample at the site of measurement of sAGEs.
The participants at the site where sAGEs were measured
differed from the eligible participants in the overall OAI
sample in that a higher percentage were women, there
were fewer African Americans, more past or present
smokers, greater abdominal circumference, lower diastolic
blood pressure, less hypertension, lower K/L grades and
less change in JSW.
The percentage of men and women with worsening JSN
are given by tertile of sAGEs in Table 2, comparing a crude
model and fully adjusted models of age, BMI, K/L grade, rim
distance and beam angle. In all models there was a mono-
tonically increased relationship between worsening JSN and
sAGEs in men but not in women, with 9%, 16.9% and 20.9%
progression in men in the base models and 13.7%, 19.6%
and 13.4% in women in the base models. Adjusting for age,
BMI, and K/L grade individually in men had little effect on
the estimates and with full adjustment the test for trend
remained statistically significant (p= 0.03). For women the
null results (p for trend = 0.93) persisted with adjustment for
potential confounding (p for trend = 0.33).
Measured change in JSW at a fixed point in the medial
tibia as a measure of progression of OA by tertile of
sAGEs are given in Table 3, comparing crude, and fully
adjusted models of age, BMI, and K/L grade. In the
crude model in men there was a significant monotonic-
ally increased relationship between JSW by tertile of
sAGEs (p for trend = 0.02). However in the full model (p
for linear trend = 0.15) the relationship was no longer
statistically significant. Similar to the JSN analysis, there
was no relationship between tertiles of sAGEs and loss
of JSW in women over serial yearly measurements.
We performed several sensitivity analyses, adding pa-
tients with diabetes mellitus to our study population,
and only evaluating the white participants due to con-
cerns that the skin autofluorescence would be affected
by skin pigmentation. Including patients with diabetes
mellitus did not materially affect our results, with a sig-
nificant p value for trend for association between tertiles
of sAGEs and JSN in men (p trend = 0.02) and no rela-
tionship in women (p = 0.27). Similarly, in comparing
tertiles of sAGEs and changes in JSW there was a non-
significant trend (p = 0.14) in men and no relationship in
women (p = 0.84). Evaluating white participants only
reduced the sample size, and while a similar result was
found in terms of trends in men compared to women,
they were no longer statistically significant (p = 0.08 and
0.39, respectively, for JSN and p = 0.26 and 0.94, respect-
ively, for changes in JSW.
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Discussion
In this study of progression of knee OA, using semi-
quantitative measurements (of JSN) we found that
higher levels of skin AGEs were associated with progres-
sion of medial-tibial knee OA in men but not in women,
and identified a trend using serial measurements of loss
of JSW. These results provide preliminary evidence sup-
porting the hypothesis that AGEs may play an important
role in the progression of knee OA, particularly in men.
In the CHECK cohort, Vos et al. [13, 14] demonstrated
an association between skin pentosidine and more severe
knee OA at baseline, but only a modest association with
progression of a combined score of hip and knee OA.
Using skin biopsies and measurements of skin pentosi-
dine levels, they did show a weak association (r = 0.167,
p = 0.02) between skin pentosidine levels and K/L score
for progression in the hip and knee. This relationship
persisted when adjusted for age and BMI. They did not
present any sex-specific findings or evaluate a sex-based
interaction effect. Using measurements of urinary pentosi-
dine, Hunter et al. did not find any association with cartil-
age loss in the knee [15]. However, the ability of urinary
pentosidine in the setting of normal renal function to
reflect the effect of AGEs on cartilage is unknown.
In our study, we identified progression of OA with
increased skin AGE levels in men and not in women,
suggesting sex differences in the effect of skin AGEs on
the progression of OA. This finding could be spurious
or could suggest that there are unique sex-specific
mechanistic pathways that may lie behind such differ-
ences. Sex differences in the prevalence, incidence and se-
verity of radiographic and clinical OA are well-described
[29, 30], but specific examination of sex differences in
MRI biomarkers or in biomarkers of joint metabolism are
few, and results vary considerably [31, 32].
Men compared women have less prevalent and incident
knee OA and less severe OA after the age of 55 years
[29, 30]. MRI suggests that women have a smaller
volume of lower knee cartilage compared to men [31].
Women have higher levels of bone resorption biomarkers
[32] whereas men have higher levels of serum hyaluronan
(HA), an indicator of synovial inflammation [33].
Karvonen-Guteirrez, Sowers and Heeringa [34] reported
relationships between cardiometabolic risk factors and
knee OA that were unique to each gender and to obesity
status. In non-obese men, BMI and homeostasis model
assessment-insulin resistance (HOMA-IR) and leptin,
were the risk factors related to knee OA. In obese men,
Table 2 Change in joint space narrowing over 4 years by tertile of skin advanced glycation end products (sAGEs)
sAGEs Crude model Trend p value Fully adjusted model Trend p trend
Men
Tertile 1: 18.7–28.0 9.02% 0.010 6.99% 0.028
Tertile 2: 28.1–33.7 16.88% 15.98%
Tertile 3: 33.9–69.5 20.92% 17.72%
Women
Tertile 1: 17.8–24.8 13.67% 0.932 11.39% 0.328
Tertile 2: 24.9–28.9 19.6% 14.39%
Tertile 3: 29.0–59.7 13.39% 8.44%
Table 3 Change in joint space width over 4 years by tertile of skin advanced glycation end products (sAGEs)
sAGEs Crude model Trend p value Fully adjusted model Trend p value
Men
Tertile 1: 18.7–28.0 0.208 (0.058) 0.023 0.247 (0.060) 0.154
Tertile 2: 28.1–33.7 0.288 (0.059) 0.292 (0.058)
Tertile 3: 33.9–69.5 0.384 (0.057) 0.374 (0.059)
Women
Tertile 1: 17.8–24.8 0.216 (0.034) 0.523 0.209 (0.035) 0.838
Tertile 2: 24.9–28.9 0.246 (0.036) 0.219 (0.036)
Tertile 3: 29.0–59.7 0.184 (0.035) 0.194 (0.035)
Mean change in joint space width (SE) in mm
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BMI was not related to knee OA, but HOMA-IR was
strongly related to it. In non-obese and obese women,
BMI continued to be a strong predictor of knee OA; how-
ever, HOMA-IR was inversely related to knee OA in obese
women. In non-obese and obese men, leptin was found to
be inversely related to the presence of radiographic OA,
whereas leptin was positively associated with radiographic
knee OA in obese women. These findings suggest
that the effects of metabolic factors on knee OA are
different in men and women, similar to our findings
related to sAGEs. Indeed, insulin resistance, elevated
insulin-like growth factor (IGF)-1, and AGEs are all
related to body fat distribution and adipocyte biology,
which might partially explain the gender difference
found in our study [35–39].
Strengths and limitations
The strengths of this study include the novel use of skin
intrinsic fluorescence as a surrogate measure of sAGEs
and the use of both JSN and JSW as measures of cartil-
age loss and thus, progression of knee OA. The limita-
tions include the single measurement of skin intrinsic
fluorescence at 36 months, while progression was deter-
mined yearly from time zero to 48 months, and thus, a
clear temporal sequence potentially reflecting a cause
and effect relationship is not present in this study. It is
thought that skin fluorescence captures the cumulative
exposure of AGEs in collagen and is relatively stable
over time compared to serum or urinary pentosidine
[17–20]. However, dietary AGEs, trace metals, cigarette
smoking and other enzymatic co-factors may affect
sAGEs and thus, the stability of a single measurement of
sAGEs needs further study. It should, however, be noted
that single measures of skin fluorescence are associated
with increased risk of diabetes mellitus, cardiovascular
disease, renal disease and mortality [2–6].
In addition, given the large number of exclusions and
the study being performed at a single site, concerns
about selection bias and generalizability are of concern.
The lack of difference between included and excluded
individuals and between knees for most covariates within
the site of measurement of sAGEs is reassuring as it sug-
gests that selection bias is unlikely to explain our results.
The lesser changes in JSW in our analytic cohort com-
pared to those excluded at the site of measurement of
sAGEs would make it harder to find a significant associ-
ation, so we may be underestimating the effect of sAGEs
on changes in JSW.
We identified a stronger association using semi-
quantitative measurement of JSN as a measure of pro-
gression compared to the quantitative measurement of
changes in JSW, due to greater sensitivity to change
using JSN. This may be related to the fact that JSN
measurements use serial evaluation of knee radiographs
by experienced musculoskeletal radiologists ordered by
time, whereas JSW is measured independent of time
using a computerized grid system. When comparing
changes in JSW, subtle progression of OA that may be
missed due to alignment issues obscuring these changes
over the same time period may be picked up by experi-
enced musculoskeletal radiologists.
The differences in sex, race and baseline K/L grade in
our sample when compared to the overall OAI sample
limits the generalizability of our findings and highlights
the need for replication of our findings in additional
cohorts. Indeed, while the sex differences appear strong
they may be spurious due to the relatively small sample
size. Elevated sAGEs are associated with pre-diabetes
mellitus and diabetes mellitus [2–5]. To account for
confounding related to the association between diabetes
mellitus with OA and with sAGEs, we excluded partici-
pants with known diabetes mellitus; however, this
reduced our sample size. We therefore performed add-
itional sensitivity analyses including the 43 patients
known to have diabetes mellitus, and the results were
nearly identical.
Conclusion
While biomechanical factors are clearly involved in
the development and progression of knee osteoarth-
ritis, systemic pathways including innate immunity,
inflammation and advanced glycation endproducts are
increasingly being recognized as playing a potentially
important role in the natural history of osteoarthritis.
This study adds credence to this view of the patho-
physiology of knee osteoarthritis and suggests that
future studies should be performed to examine the
advanced glycation endproduct hypothesis.
Additional file
Additional file 1: Table S1. Comparison of included/excluded but
otherwise eligible* groups in OAI. *otherwise eligible means the OAI
participant met all inclusion criteria (no diabetes, baseline and at least
one followup xray, KL grade <4, no lateral knee disease) but didn't have a
sAGE reading performed at 36 months. (DOC 66 kb)
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